Company intelligence / Profile preview

Vistin Pharma

Ownership: Private
Employees: ~77
Development stage: Commercial

Overview

Vistin Pharma produces about 10% of the world’s supply of metformin HCl active pharmaceutical ingredient (API) and direct compressible granules. The company operates a state-of-the-art cGMP-certified facility in Norway that has been successfully inspected by the US FDA. An expansion project initiated in 2022 aims to double capacity to reach up to a projected 15% global market share. Their product meets high purity standards with no detectable nitrosamines or significant impurities and features sustainable production using renewable hydropower.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

metformin

Commercial

Indications: Type 2 diabetes

Beyond the preview

Go deeper on Vistin Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vistin Pharma.

Explore the full profile